

ASX Announcement

2 October 2020

First quarter sales update

Genetic Signatures Limited (ASX: GSS), today advises that preliminary sales for the quarter ended 30 September 2020 are approximately \$10.5 million, 50% higher than the previous quarter ended 30 June 2020. The Company had previously indicated in the commentary accompanying the FY2020 financial results that sales would be at least 25% greater than the previous quarter.

Full commentary will be provided with the release of the Appendix 4C and quarterly update due for release later in October 2020.

For further information, see www.geneticsignatures.com or contact:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

Announcement authorised by Genetic Signatures' Board of Directors

About Genetic Signatures Limited

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.